keyword
MENU ▼
Read by QxMD icon Read
search

fgf 23 normal reference range

keyword
https://www.readbyqxmd.com/read/19929273/a-prospective-study-of-fibroblast-growth-factor-23-in-children-with-chronic-kidney-disease
#1
Per Magnusson, Sverker Hansson, Diana Swolin-Eide
BACKGROUND: Fibroblast growth factor-23 (FGF-23) is a novel regulator of phosphate metabolism; however, the clinical knowledge is limited in children with chronic kidney disease (CKD) who are at risk of developing mineral bone disorder. METHODS: This prospective study over 2 years investigated the development of bone mass and bone turnover in relation to serum FGF-23 in children with CKD. Thirteen patients, 4-15 years, were included with a median corrected glomerular filtration rate (GFR) of 38 (range 7-74) mL/min/1...
February 2010: Scandinavian Journal of Clinical and Laboratory Investigation
https://www.readbyqxmd.com/read/15121023/resolution-of-severe-adolescent-onset-hypophosphatemic-rickets-following-resection-of-an-fgf-23-producing-tumour-of-the-distal-ulna
#2
L M Ward, F Rauch, K E White, G Filler, M A Matzinger, M Letts, R Travers, M J Econs, F H Glorieux
Oncogenic hypophosphatemic osteomalacia (OHO) is an uncommon hypophosphatemic syndrome characterized by bone pain, proximal muscle weakness and rickets. It has been postulated that OHO results from overproduction of a humoral phosphaturic factor by an occult tumour. Recently, some OHO tumours have been shown to elaborate fibroblast growth factor-23 (FGF-23), which causes renal phosphate wasting when administered to mice. The purpose of this study was to undertake detailed investigations to confirm the diagnosis of OHO in a pediatric patient and to document the biochemical, radiographic and bone histological phenotype before and after tumour removal...
May 2004: Bone
https://www.readbyqxmd.com/read/12711740/fibroblast-growth-factor-23-in-oncogenic-osteomalacia-and-x-linked-hypophosphatemia
#3
Kenneth B Jonsson, Richard Zahradnik, Tobias Larsson, Kenneth E White, Toshitsugu Sugimoto, Yasuo Imanishi, Takehisa Yamamoto, Geeta Hampson, Hiroyuki Koshiyama, Osten Ljunggren, Koichi Oba, In Myung Yang, Akimitsu Miyauchi, Michael J Econs, Jeffrey Lavigne, Harald J├╝ppner
BACKGROUND: Mutations in fibroblast growth factor 23 (FGF-23) cause autosomal dominant hypophosphatemic rickets. Clinical and laboratory findings in this disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23 messenger RNA, and to those in X-linked hypophosphatemia, which is caused by inactivating mutations in a phosphate-regulating endopeptidase called PHEX. Recombinant FGF-23 induces phosphaturia and hypophosphatemia in vivo, suggesting that it has a role in phosphate regulation...
April 24, 2003: New England Journal of Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"